HIMS
Hims & Hers Health, Inc. · Healthcare · Medical - Care Facilities
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 118 | +5 | 113.73M | $3.93B | +12 | −7 |
| Q1 2026 | 116 | -11 | 106.84M | $2.21B | +5 | −17 |
| Q4 2025 | 126 | 0 | 156.98M | $5.10B | +3 | −2 |
| Q3 2025 | 18 | -3 | 142.80M | $8.10B | +1 | −5 |
| Q2 2025 | 19 | +2 | 90.37M | $4.50B | +2 | — |
| Q1 2025 | 14 | 0 | 34.98M | $1.03B | +1 | −1 |
| Q4 2024 | 14 | 0 | 32.53M | $786.65M | +1 | −1 |
| Q3 2024 | 13 | -1 | 22.65M | $417.14M | — | −1 |
| Q2 2024 | 14 | — | 23.02M | $464.79M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 6.04M | — | $121.94M | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 3.81M | — | $76.88M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 3.81M | — | $76.88M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Two Sigma Investments ✦ | 2.60M | — | $52.39M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 2.56M | — | $51.71M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 2.56M | — | $51.71M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 2.56M | — | $51.71M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 2.56M | — | $51.71M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 2.56M | — | $51.71M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 2.21M | — | $44.54M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 2.18M | — | $44.06M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Millennium Management ✦ | 1.97M | — | $39.83M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Oaktree Capital Management ✦ | 666.96K | — | $13.47M | 0.3% | n/c | 1 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 457.54K | — | $9.24M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 457.54K | — | $9.24M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 195.44K | — | $3.95M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 195.44K | — | $3.95M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Bridgewater Associates ✦ | 183.82K | — | $3.71M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Arrowstreet Capital ✦ | 88.46K | — | $1.79M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 47.89K | — | $966,838 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 47.89K | — | $966,838 | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 47.89K | — | $966,838 | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Gotham Asset Management ✦ | 16.07K | — | $324,393 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 430 holders, 143.91M shares, $2.91B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.94K sh · $148,111
Officer · 25.11K sh · $691,808
Officer, Director · 16.77K sh · $467,128
Officer · 9.39K sh · $261,802
Officer · 55.38K sh · $1.94M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology